Evaluation of serum adropin and irisin levels and its association with anthropometric obesity indices and biochemical parameters in Type 2 diabetic patients

Alzoughool, Foad; Hourani, Huda Al; Atoum, Manar; Bateineh, Sajedah; shaikh, Hanan Abu; Al-Zghool, Hamza; Al‐Shudifat, Abdel‐Ellah

doi:10.3233/nha-200110

Cited by 3 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They demonstrated that irisin levels strongly correlated with weight, BMI, waist circumference and W/H ratio. In agreement with our results, Alzoughool et al [17] . The aim of this research is to evaluate the levels of serum irisin in persons diagnosed with T2DMand explore any possible ~ 20 ~ correlations between serum irisin, anthropometric obesity indices, and biochemical markers.…”

Section: Discussionsupporting

confidence: 94%

The relation between serum irisin levels with the anthropometric and metabolic parameters in obese and non-obese patients with type 2 diabetes mellitus

Elmetwaly,

AboELnasr,

Soliman

et al. 2023

Int. J. Adv. Res. Med.

View full text Add to dashboard Cite

Background: The browning of white adipose tissue caused by irisin, which has a role in thermogenesis. The purpose of this research was to assess the irisin in individuals with type 2 diabetes mellitus (T2DM), comparing obese and non-obese patients, to evaluate its correlation with metabolic and anthropometric parameters. Methods: This survey work setting was done on 200 patients with clinical criteria of type two diabetes mellitus. Patients were categorized in to 2 groups according to body mass index (BMI): group I: 94 patients with obese type 2 DM and Group II: 106 patients with non-obese type 2 DM. Detection and quantification of Irisin in human and mouse plasma, serum, urine, cell, and tissue lysates were performed using Irisn Elisa Kits. Results: A significant positive correlation was between irisin levels and anthropometric measures. Conversely, a significant negative correlation was found between irisin levels and indicators of fat-free mass. There was an insignificant correlation between irisin and parameters as (Height, systolic BP, diastolic BP, total cholesterol, triglycerides, HDL and LDL). Conclusion:The elevation in irisin levels in individuals with obesity may suggest a physiological role in enhancing glucose tolerance, a common impairment observed in obese individuals. However, this compensatory irisin secretion seems to transition towards a state of inadequate secretion as diabetes develops. Irisin has the ability to have beneficial effects on glucose and insulin levels.

show abstract

Section: Discussionsupporting

confidence: 94%

The relation between serum irisin levels with the anthropometric and metabolic parameters in obese and non-obese patients with type 2 diabetes mellitus

Elmetwaly,

AboELnasr,

Soliman

et al. 2023

Int. J. Adv. Res. Med.

View full text Add to dashboard Cite

show abstract

“…The finding of the current study agreed with results previously reported by (43) that found serum Adropin levels were inversely correlated with adverse metabolic parameters including FBS, HbA1C, HOMA-IR and fasting insulin and agreed with (44), as well as (45)showed opposite to current study which reported Serum adropin has negative correlation with HbA1C and fasting insulin and BMI , one possible reason that adropin plays an important role in maintaining metabolic homeostasis, increasing glucose utilization at the expense of fatty acids, improving glucose tolerance, and reducing insulin resistance. The differences between the studies it was highly probable that our observations in T2DM were confounded by variations in disease duration, diabetic complications Metabolically, adropin regulates the activities of the principal pancreatic hormones that control the fate of glucose and fatty acids.…”

Section: Discussionsupporting

confidence: 93%

Determination of adropin, body mass index and other biochemical parameters in Iraqi type II diabetic patients

Chachan

Farhna

Hamed

et al. 2022

ijhs

View full text Add to dashboard Cite

Evidence suggests a hormone peptide named adropin, is involved in lipid metabolism, insulin resistance, and obesity. However, its role in pathogenesis of type 2 diabetes mellitus (T2DM) is still unclear in humans. Therefore, we investigated whether adropin levels are altered in T2DM patients, and evaluated its association with diabetes- related parameters. Samples which collected from 180 subjects were divided into case group [n = 90] and control groups [n = 90]. The mean age was [43.17 ±11.13] years. Men (n=81) and femanl (n=99) were participated in case-control study. Serum adropin levels were determined by ELISA. The mean serum adropin level was significantly higher [P<0.01] in the control group compared to case group [6.9±1.3 vs. 5.8±1.2] respectively. The result shown there was a significant difference [P-value<0.001] between body mass index and adropin. adropin with high significant negative correlation [P-value<0.001] between adropin and body mass index, fasting blood sugar, glycated hemoglobin, insulin, and homeostatic model assessment for insulin resistance also a significant negative correlation was found between the adropin and low-density lipoprotein, triglyceride, very low-density lipoprotein and no significant with cholesterol, high-density lipoprotein.

show abstract

“…Therefore, agents with the ability to improve hepatic insulin resistance by reducing hepatic fat content, inflammation and proinflammatory cytokines are urgently needed to treat T2D and obesity. Several studies demonstrated that in humans, circulating adropin level is inversely correlated with body mass index (BMI) [ 14 , 15 , 16 ]. Furthermore, it has been found that adropin deficiency in mice is accompanied by adiposity as well as impaired insulin sensitivity [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Daily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile, Reduces Hepatic Lipid Content and Restores Elevated Hepatic Enzymes in Serum

Skrzypski

Kołodziejski

Pruszyńska‐Oszmałek

et al. 2022

IJMS

View full text Add to dashboard Cite

Adropin is a peptide hormone encoded by Energy Homeostasis Associated gene. Adropin modulates energy homeostasis and metabolism of lipids and carbohydrates. There is growing evidence demonstrating that adropin enhances insulin sensitivity and lowers hyperlipidemia in obese mice. The aim of this study was to investigate the effects of daily administration of adropin for four weeks in mice with experimentally induced type 2 diabetes (T2D). Adropin improved glucose control without modulating insulin sensitivity. Adropin reduced body weight, size of adipocytes, blood levels of triacylglycerol and cholesterol in T2D mice. T2D mice treated with adropin had lower liver mass, reduced hepatic content of triacylglycerol and cholesterol. Furthermore, adropin attenuated elevated blood levels of hepatic enzymes (ALT, AST, GGT and ALP) in T2D mice. In T2D mice, adropin increased the circulating adiponectin level. Adropin had no effects on circulating insulin and glucagon levels and did not alter pancreatic islets morphology. These results suggest that adropin improves glucose control, lipid metabolism and liver functions in T2D. In conjunction with reduced lipid content in hepatocytes, these results render adropin as an interesting candidate in therapy of T2D.

show abstract

Evaluation of serum adropin and irisin levels and its association with anthropometric obesity indices and biochemical parameters in Type 2 diabetic patients

Cited by 3 publications

References 34 publications

The relation between serum irisin levels with the anthropometric and metabolic parameters in obese and non-obese patients with type 2 diabetes mellitus

The relation between serum irisin levels with the anthropometric and metabolic parameters in obese and non-obese patients with type 2 diabetes mellitus

Determination of adropin, body mass index and other biochemical parameters in Iraqi type II diabetic patients

Daily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile, Reduces Hepatic Lipid Content and Restores Elevated Hepatic Enzymes in Serum

Contact Info

Product

Resources

About